Key result
Digital health technology offers new possibilities for objective measurements in Parkinson's disease trials, but requires rigorous analytical and clinical validation to ensure clinical meaningfulness.
Why the study?
Digital health technology may offer objective measurements in Parkinson's disease, but challenges remain in verifying, validating, and identifying standard measurements that capture meaningful benefits in clinical trials.
Digital health technologies offer potential for objective, frequent measurement in Parkinson's disease trials, but require rigorous analytical and clinical validation to ensure regulatory and clinical utility.
Answers are grounded in this paper and cite their sources.
Requires rigorous validation before digital PD measures enter trials; leaves open standardized frameworks for regulatory and clinical adoption.
Digital health technology (DHT), including wearable and environmental sensors, video cameras and other electronic tools, has provided new opportunities for the measurement of movement and functionality in Parkinson's disease. Compared to current standards for evaluation of the disease (MDS-UPDRS), DHT may offer new possibilities for more frequent objective measurements of the duration, severity and frequency of disease manifestations over time, that may provide more information than periodic clinic visits. However, DHT measurements are only scientifically and medically useful if they are accurate, reliable and clinically meaningful. Verification and validation, also known as analytical validation and clinical validation, of DHT performance is important to ensure the accuracy and precision of measurements, and the specificity of findings. Given the wide range of clinical manifestations associated with Parkinson's disease and the many tools and metrics to assess them, the challenge is to identify those that may represent a standard for use in clinical trials, and to confirm when digital measurements succeed or fall short of capturing meaningful benefits during drug development.
No takes yet. Share an insight, caveat, or question.
Sacks et al. (2021) conducted a review in Parkinson's disease. Digital health technology (DHT) vs. MDS-UPDRS was evaluated. Digital health technology offers new possibilities for objective measurements in Parkinson's disease trials, but requires rigorous analytical and clinical validation to ensure clinical meaningfulness.
Synapse has enriched 10 related papers. Consider them for comparative context: